A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)
Latest Information Update: 24 May 2024
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SPRING
- Sponsors Novartis Pharmaceuticals
- 21 May 2024 Planned End Date changed from 28 Feb 2025 to 27 Jan 2026.
- 21 May 2024 Planned primary completion date changed from 28 Feb 2025 to 27 Jan 2026.
- 25 Oct 2022 Planned End Date changed from 15 Oct 2024 to 28 Feb 2025.